Classification and Molecular Mechanism of Action
Potassium-sparing diuretics are divided into two main subclasses that act on the same segments of the nephron but have completely different cellular targets.
- Sodium channel blockers (triamterene, amiloride). These agents act as direct blockers. They physically occlude the epithelial sodium channels (ENaC) located on the apical membrane of principal cells. Consequently, sodium cannot enter the cell and is excreted in the urine.
- Mineralocorticoid receptor antagonists (spironolactone, eplerenone). These are competitive antagonists of aldosterone and deoxycorticosterone receptors. Their target is intracellular receptors. Under normal conditions, aldosterone stimulates the synthesis of proteins for new ENaC and $Na^+/K^+$-ATPase pumps, enhancing sodium reabsorption and potassium excretion. These drugs exert the exact opposite effect: by binding to the receptor, they block it and inhibit the synthesis of new channels, thereby reducing membrane permeability to sodium.
The net effect of both groups is identical: decreased sodium reabsorption (excreted along with equivalent volumes of water) and decreased potassium secretion (potassium-sparing effect).
Pharmacokinetics and Diuretic Characteristics
The diuretic efficacy of potassium-sparing agents is considered quite moderate. Furthermore, drugs acting on intracellular receptors exhibit distinct temporal characteristics.
For example, the diuretic effect of spironolactone (trade names: Aldactone, Veroshpiron) develops very slowly. The latent period ranges from 2 to 5 days from the start of therapy. This delay is due to pharmacokinetics and the time required for target cells to alter protein synthesis. Notably, after drug discontinuation, its residual effects persist for several days.
Dosing Regimen:
- Administration in divided daily doses is recommended.
- They are preferably taken on an empty stomach.
- Administration should strictly occur in the first half of the day to avoid nighttime diuresis and sleep disturbance.
Clinical Application and Combination Therapy
The primary strategy for using these agents is combination therapy. It is rational to prescribe them alongside potassium-wasting diuretics (loop or thiazide diuretics). A classic example of such a combination is hydrochlorothiazide + triamterene, which effectively maintains plasma potassium homeostasis.
Independent and specific indications include:
- Edematous states pathogenetically linked to mineralocorticoid (aldosterone) excess. This includes primary and secondary hyperaldosteronism, such as in chronic heart failure and liver cirrhosis.
- Hypertension.
- Liddle syndrome. This is a rare hereditary form of hypertension caused by ENaC mutations that lead to channel hyperactivity. Direct sodium channel blockers are the drugs of choice in this condition.
Safety Profile and Adverse Effects
Despite their moderate diuretic potency, these drugs carry significant side effects requiring monitoring:
- Electrolyte disturbances: The primary risk during chronic use is the retention of ions leading to hyperkalemia.
- Systemic and allergic reactions: Hypotension (excessive blood pressure reduction) and skin rashes may occur.
- Gastrointestinal disturbances: Patients may complain of nausea, vomiting, and diarrhea.
- Endocrine abnormalities: Specific to spironolactone. Due to its steroid chemical structure, it can cross-react with other steroid receptors (androgen and progesterone). In men, this can manifest as impotence and gynecomastia, and in women, as menstrual irregularities.